The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about McKesson (MCK) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.McKesson currently has an average ...

McKesson (MCK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over the past month, shares of this prescription drug distributor have returned +20.3%, compared to the Zacks S&P 500 composite's +3% change. During this period, the Zacks Medical - Dental Supplies industry, which McKesson falls in, has gained 7%. The key question now is: What could be the stock's future direction? While m ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, it's pretty easy to find cutting-edge growth stocks with the help of the Zacks Gro ...

Analyst’s Disclosure: I/we have a beneficial long position in the shares of MCK either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any in ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 1-13252 McKESSON CORPORATION (Exact name of registrant as specified in its charter) Delaware 94-3207296 (State or other ...

Core Insights - McKesson Corporation reported strong second-quarter fiscal 2025 results, with adjusted earnings per share (EPS) of $7.07, exceeding the Zacks Consensus Estimate of $6.89 by 2.6% and showing a year-over-year improvement of 13.5% [1] - Revenues reached $93.65 billion, surpassing the Zacks Consensus Estimate by 4.7% and reflecting a year-over-year increase of 21.3%, driven by growth in the Pharmaceutical segment, particularly specialty products and GLP-1 medications [2][12] Revenue Details - The U.S. Pharmaceutical segment generated revenues of $85.7 billion, up 23% year over year, primarily due to increased prescription volumes from specialty products and GLP-1 medications [4] - The International segment reported revenues of $3.7 billion, a 7% increase year over year, attributed to higher pharmaceutical distribution volumes in Canada [5] - The Medical-Surgical Solutions segment's revenues totaled $2.9 billion, up 4% year over year, driven by higher volumes of specialty pharmaceuticals [7] - The Prescription Technology Solutions segment achieved revenues of $1.3 billion, an 11% increase year over year, supported by growth in technology services and third-party logistics [8] Profitability Metrics - Gross profit for the quarter was $3.25 billion, a 5.8% increase year over year, representing 3.5% of net revenues, down nearly 50 basis points from the previous year [9] - Operating income was reported at $578 million, down 39.2% year over year, with an operating margin of 0.6%, a decline of almost 60 basis points [9] Financial Update - Cash and cash equivalents stood at $2.51 billion, up from $2.3 billion a year ago, with cumulative net cash provided by operating activities amounting to $720 million compared to a net cash used of $87 million in the prior year [10] Fiscal 2025 Guidance - McKesson raised its adjusted EPS guidance for fiscal 2025 to a range of $32.40-$33.00, reflecting an 18-20% growth from the prior year, with revenues expected to grow 15-17% [11] Market Performance - McKesson's shares rose 4.7% in after-hours trading following the earnings report, with an 18.8% increase year to date, outperforming the industry growth of 2.9% and the S&P 500 Index's gain of 24.7% [3]

McKesson MCK reported better-than-expected second-quarter financial results on Wednesday.McKesson reported quarterly earnings of $7.07 per share which beat the analyst consensus estimate of $6.88 per share. The company reported quarterly sales of $93.70 billion which beat the analyst consensus estimate of $89.33 billion.McKesson shares gained 4.6% to close at $549.31 on Wednesday.These analysts made changes to their price targets on McKesson following earnings announcement.Baird analyst Eric Coldwell upgrad ...

McKesson Corporation (NYSE:MCK) Q2 2025 Earnings Conference Call November 6, 2024 4:30 PM ET Company Participants Rachel Rodriguez - VP of Investor Relations Brian Tyler - Chief Executive Officer Britt Vitalone - Executive Vice President and Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Kevin Caliendo - UBS Daniel Grosslight - Citi Charles Rhee - TD Cowen Brian Tanquilut - Jeffries Elizabeth Anderson - Evercore ISI Eric Percher - Nephron Research Stephanie Davis - Barclays Stephe ...

McKesson (MCK) reported $93.65 billion in revenue for the quarter ended September 2024, representing a year-over-year increase of 21.3%. EPS of $7.07 for the same period compares to $6.23 a year ago. The reported revenue represents a surprise of +4.66% over the Zacks Consensus Estimate of $89.48 billion. With the consensus EPS estimate being $6.89, the EPS surprise was +2.61%. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determi ...

McKesson (MCK) came out with quarterly earnings of $7.07 per share, beating the Zacks Consensus Estimate of $6.89 per share. This compares to earnings of $6.23 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of 2.61%. A quarter ago, it was expected that this prescription drug distributor would post earnings of $7.16 per share when it actually produced earnings of $7.88, delivering a surprise of 10.06%. Over the last four quarters ...